

GLAXOSMITHKLINE PLC  
Form 6-K  
February 20, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February, 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notificati  
on of Transactions of Directors and  
Persons Discharging Managerial Responsibility**

I give below details of changes in the interests of

:

- Directors and  
Persons Discharging Managerial Responsibility  
in the Ordinary s  
hares of GlaxoSmithKline plc in respect of the  
under  
mentioned  
persons  
arising from the  
sale  
of Ordinary  
s  
hares at a price of  
£11.91  
per Ordinary Share on  
19 February 2009  
to meet their tax liabilities following the vesting of a Performance Share Plan (PSP) award  
:

**No**

.

**of Ordinary**

**s**

**hares sold to meet tax liabilities following the vesting of a PSP  
award**

Dr M	6,188
M	
Slaoui*	
Mr S M Bicknell	1,293
Mr E J Gray	2,738
Mr D Learmouth	1,293
Ms C Thomas	2,060
Mr D	2,738
S	
Redfern	

\* Denotes an Executive Director

- Persons

Discharging Managerial Responsibility in the  
American Depositary Shares (ADSs)  
of GlaxoSmithKline plc in respect of the under mentioned  
persons  
arising from the  
withholding of shares  
at a price of  
\$33.42

per  
ADS  
on  
19

February 2009

to meet their tax liabilities following the vesting of a Performance Share Plan award  
:

**No**

.

**of  
ADSs**

**withheld**

**to meet tax liabilities following the vesting of a PSP award**

Mr W C Louv

990

\* Denotes an Executive Director

The Company, Directors, Persons Discharging Managerial Responsibility were advised of these  
transactions on  
20 February 2009  
.

This notification relates to a transaction notified in accordance with

Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Deputy  
Company Secretary

20 February 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 20, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc